Background The intracellular mechanism of coronary artery spasm is still unknown. The pathway mediated by protein kinase C (PKC) is an important intracellular process of various cellular responses, including vascular smooth muscle contraction. Thus, we examined the role of the PKC-mediated pathway in the pathogenesis of coronary artery spasm in our in vivo swine model.
Background The intracellular mechanism of coronary artery spasm is still unknown. The pathway mediated by protein kinase C (PKC) is an important intracellular process of various cellular responses, including vascular smooth muscle contraction. Thus, we examined the role of the PKC-mediated pathway in the pathogenesis of coronary artery spasm in our in vivo swine model.
Methods and Results Seven Gottingen miniature pigs underwent coronary balloon injury and x-ray irradiation to induce atherosclerotic lesion. After 6 to 18 months, intracoronary serotonin (3 ,ug/kg) or histamine (3 ,ug/kg) repeatedly induced coronary artery spasm at the atherosclerotic site. At the spastic site, intracoronary administration of phorbol-12,13-dibutyrate (PDBu) (10-9 mol/kg), a PKC-activating phorbol ester, also induced coronary artery spasm, which was completely blocked by pretreatment with intracoronary staurosporine (10 ,g/kg), a PKC inhibitor. Intracoronary administration of an inactive phorbol ester, phorbol-12,13-didecanoate (10-9 mol/kg), did not induce coronary vasoconstriction. Coronary artery spasm C oronary artery spasm plays an important role in the pathogenesis of a wide variety of ischemic heart diseases, not only in variant angina but also in unstable angina, myocardial infarction, ventricular arrhythmias, and sudden death. [1] [2] [3] [4] However, the pathogenesis of coronary spasm is still unknown, and the elucidation of its mechanism remains an important clinical issue. We have developed a swine model of coronary spasm5-7 and revealed several pathogenetic aspects of the spasm. In our swine model, smooth muscle contraction to autacoids (serotonin and histamine) is augmented, endothelium-dependent relaxations to the autacoids are reduced,8'9 and calcium sensitivity of the contractile proteins in smooth muscle per se is not augmented at the spastic site. 10 Thus, the key mechanism(s) for smooth muscle hyperconstriction appears to exist in the signal transduction pathway at a level between receptors and the contractile proteins.
The 10`mol/kg) and for 20 minutes after that of PDD (10m ol/kg). These doses of PDBu were determined in the preliminary study so that the estimated maximum concentration of PDBu (10`9mol/kg) was 10-7 mol/L when the phorbol ester was injected into the left coronary arteries for 3 minutes. The same dose (10`mol/kg) was chosen for PDD. The different durations of the coronary arteriographic study for PDBu (60 minutes) and PDD (20 minutes) were determined based on the preliminary findings that the vasoconstrictor effect of PDBu (10`mol/kg) lasts for 60 minutes and that PDD (10m ol/kg) causes no coronary vasoconstriction. We also confirmed in the preliminary study that the vasoconstrictor effect of PDBu was reproducible. Care was taken so that the injected volume of PDD and PDBu (dissolved in physiological salt solution containing less than 5% dimethyl sulfoxide) was 6 mL and the injection time was 3 minutes. We confirmed in the preliminary study that the dimethyl sulfoxide solution alone did not affect the coronary diameter. Intracoronary staurosporine (10 ,ug/kg) was given 5 minutes before intracoronary administration of PDBu at 10`mol/kg, and coronary arteriography was repeated after that. To examine the effect of activation of the PKC-mediated pathway on serotonin-and histamine-induced coronary vasoconstriction, coronary arteriography after intracoronary administration of those autacoids was repeated 5 minutes after staurosporine (10 jug/kg) and more than 60 minutes after PDBu (10-9 mol/kg) when the coronary diameters almost returned to the control level. At the end of the experiments, coronary arteriography was repeated after intracoronary administration of nitroglycerin (10 gg/kg). Protocol 2 Coronary artery vasomotion was examined in response to intracoronary administration of Bay K 8644, a dihydropyridine-sensitive L-type Ca' channel agonist,'8 before and after intracoronary administration of staurosporine and nifedipine. 19 Coronary arteriography was performed 2 minutes after intracoronary administration of Bay K 8644 (1, 3, and 10 ,g/kg). Intracoronary staurosporine (10 gg/kg) or nifedipine (0.1 mg/kg) was given 5 minutes before intracoronary administration of Bay K 8644 (10 ag/kg).
Coronary Diameter Measurement
Cineangiograms at end diastole were chosen and printed, and the coronary luminal diameters were measured with calipers. With this technique, excellent correlations between repeated measurements (r=.99) and between different observers (r=.98) were confirmed in the range of the coronary diameter from 0.98 to 5.58 mm. The degree of constrictive response was expressed as the percent decrease in the luminal diameter from the control level. The coronary diameter was measured at the segment of the LAD where a focal excessive constriction evoked with drugs was maximal and at the segment of the left circumflex coronary artery (LCx) where the diameter was similar to that of the spastic segment of the LAD under control conditions.
Histological Examination
After the angiographic experiments, hearts were removed and the left coronary arteries were perfused by a constantpressure perfusion system (120 cm H20) with saline (500 mL) and subsequently with 6% formaldehyde (1000 mL). After the fixation, both the LAD and the LCx were cut transversely into segments at a 5-mm interval along the main trunk with small surrounded tissues. These segments were stained with hematoxylin-eosin and van Gieson's elastic staining for photomicroscopy.
Drugs
The following drugs were used: 5-hydroxytryptamine (serotonin), histamine, PGF2a,, PDD, PDBu, staurosporine (Sigma Chemical Co), Bay K 8644 (Wako Junyaku Co), and nifedipine (Bayer Pharmaceutical Co). PDD, PDBu, and staurosporine were prepared as stock solutions in dimethyl sulfoxide. Dilution was made with a physiological salt solution. Nifedipine was prepared by diluting the content of a nifedipine capsule (10 mg) in 10 mL of physiological salt solution.
Statistical Analysis
The results were expressed as mean+SEM. Multiple comparisons were made by a two-way ANOVA followed by a post hoc test, and unpaired data were analyzed by Student's t test. A value of P<.05 was considered statistically significant.
Results
At the angiographic study, pigs weighed 35 to 47 kg. Intracoronary serotonin (3 ag/kg) or histamine (3 gg/ kg) repeatedly induced coronary spasm at the previously denuded and x-irradiated LAD with ischemic ECG changes (Fig 1) . In contrast, PGF2, (50 ,g/kg) induced comparable vasoconstriction at the spastic LAD (28.2±7.9%, n=3) and at the control LCx (29.4±6.4%, n=3). At those spastic sites, PDBu (10m ol/kg) also induced coronary spasm with ischemic ECG changes (Fig 1) . The time course of phorbol ester-induced coronary vasoconstriction is shown in kg) (Fig 2) . PDD T ME(m in) staurosporine (10 gtg/kg) or nifedipine (0.1 mg/kg) (P<.01) (Fig 6) .
Histologically, intimal and medial thickening, which was compatible with atherosclerotic changes, was noted at the spastic LAD but not at the control LCx (Fig 7) . Full lining of regenerated endothelial cells at the spastic site was confirmed by electron microscopy, as we reported in the previous study. 20 Discussion The major findings of this study were (1) PDBu, a PKC-activating phorbol ester, induced coronary spasm at the atherosclerotic site, where serotonin and histamine also induced the spasm, (2) The present study demonstrates that PDBu, a PKCactivating phorbol ester, induced vasoconstriction in porcine coronary arteries in vivo and that the vasoconstriction was significantly greater at the spastic than at the control site in our swine model. The marked coronary vasoconstriction induced by PDBu (10`mol/kg) at the spastic site was accompanied by ischemic ECG changes. Thus, PDBu caused coronary spasm with myocardial ischemia, as did serotonin and histamine. Interestingly, however, PDBu-induced spasm lasted for a longer duration (response peaked at 20 minutes and was sustained for 50 to 60 minutes) than that induced by serotonin (response peaked at 2 to 3 minutes and was sustained for 5 to 7 minutes) or histamine (response peaked at 1 minute and was sustained for 3 to 4 minutes). These results are consistent with the in vitro finding that PDBu induces slowly developing contraction of isolated porcine coronary artery. 24 PDBu-induced coronary spasm was completely blocked by pretreatment with intracoronary staurosporine. An inactive phorbol ester, PDD, did not induce coronary vasoconstriction. These results suggest that the PKC-mediated pathway in vascular smooth muscle is importantly involved in the pathogenesis of coronary spasm in our swine model. We also confirmed in the subsequent in vitro studies that responsiveness of vascular smooth muscle to PDBu was greater in vessels taken from the spastic site than in those from the control site (unpublished observations).
In the present study, PDBu was administered intra- However, in the present study, serotonin-and histamine-induced coronary spasm was only partially inhibited by pretreatment with staurosporine at a concentration of 10 ,ug/kg, which abolished the PDBu-induced vasoconstriction; hyperconstriction to those autacoids still existed even after the PKC inhibition by staurosporine. In our swine model, the blockers of serotonin (ketanserin) and histamine (diphenhydramine) completely prevented the coronary spasm induced by serotonin and histamine, respectively, indicating that the signals for the hyperconstriction enter into the vascular smooth muscle exclusively through those receptors.56 Thus, these results may suggest that pathways other than the PKC-mediated one located downstream from the autacoid receptors are also involved in the pathogenesis of the spasm induced by the autacoids. The results may also suggest that the concentration of staurosporine used in the present study was relatively selective for PKC inhibition. As discussed earlier, we speculate that the mass of and/or the substrate for PKC may be increased at the atherosclerotic and spastic site. It is also possible that the signal transduction for vasoconstriction is augmented at a certain step of PKC-mediated pathway. Indeed, the role of the PKC-mediated pathway in the vascular smooth muscle hyperconstriction may be complex, and multiple sites might be involved in addition to PKC itself. Those include the dihydropyridine-sensitive L-type Ca> channel, sarcolemmal receptor-operated Ca> channels and the sarcoplasmic reticulum (SR) inositol triphosphate (IP3)/Ca2+ release channel (mechanisms allowing entry of Ca' into the cytosol upon activation), and the sarcolemmal and SR Ca 2 pumps and the sarcolemmal Na+/Ca' exchanger (mechanisms removing Ca' from the cytosol).29 Our data suggest that among those possible mechanisms, at least the interaction between the PKC-mediated pathway and the dihydropyridine-sensitive L-type Ca>2 channel may be augmented at the spastic site.
Although it was beyond the scope of this study to examine all of the possible mechanisms, another important clue was that PGF2a induced comparable coronary vasoconstriction at the spastic and control sites. This finding also has been repeatedly observed in our previous studies.20 In our swine model, phenylephrine6 and a thromboxane analogue30 also caused comparable coronary vasoconstriction at the spastic and control sites. These results may not only exclude the major contribution of the geometric theory31 but also suggest that coronary hyperreactivity is developed selectively to some agonists but not to others, probably due to the altered intracellular signal transduction mechanisms. Recently, it has been reported that in the rat basilar 
